Sonodynamic Therapy with Ferrocene-Modified Frameworks Targets Breast Cancer Metastasis

Key Takeaways

• mCOFs + ultrasound cut breast cancer cell viability to 24.3%.
• Treatment triggers five‑fold ATP release and four‑fold dendritic cell maturation.
• Mouse studies show primary tumor shrinkage and bone metastasis reduction.
• Dual ROS generation combines singlet oxygen and Fenton‑mediated hydroxyl radicals.
• Immune profiling reveals increased CD8⁺ T‑cell and NK‑cell tumor infiltration.

Pulse Analysis

Sonodynamic therapy (SDT) has gained traction because ultrasound can reach deep‑seated tumors with precise spatial control, yet the field has been hampered by sonosensitizers that either persist in the body or lack multifunctionality. Ferrocene‑modified covalent organic frameworks (mCOFs) sidestep these issues by offering a tunable, biodegradable scaffold that embeds iron‑based catalytic sites. When ultrasound excites the porphyrin backbone, singlet oxygen is produced; the ferrocene moieties then catalyze a Fenton‑like reaction, converting tumor‑derived hydrogen peroxide into highly reactive hydroxyl radicals. This dual‑ROS strategy amplifies oxidative stress, inducing both apoptosis and ferroptosis, and explains the dramatic drop in cell viability observed in vitro.

Beyond direct cytotoxicity, the mCOF platform triggers immunogenic cell death, a critical step for converting a “cold” tumor into an immunologically active one. The study reports a near‑five‑fold surge in extracellular ATP and a four‑fold rise in mature dendritic cells, both hallmarks of danger‑signal release that prime adaptive immunity. In vivo, treated mice displayed robust infiltration of CD8⁺ cytotoxic T lymphocytes, helper T cells, and natural killer cells, suggesting that the nanoplatform not only destroys tumor cells but also re‑educates the immune microenvironment. This synergy could reduce reliance on systemic chemotherapy, which often fails to reach bone metastases and carries substantial toxicity.

If translated to humans, mCOF‑based SDT could reshape the therapeutic landscape for metastatic breast cancer, a disease where bone lesions drive morbidity and mortality. The technology aligns with the broader industry shift toward combination regimens that merge physical ablation, targeted nanomedicine, and immunotherapy. Investors and biotech firms may view the platform as a modular foundation for adding checkpoint inhibitors or personalized vaccine components, potentially accelerating the pipeline of next‑generation cancer treatments.